Biologics And Biosimilars

Unlike conventional medicines that are chemically synthesized in a laboratory, biopharmaceuticals are produced using living cells  and that single distinction changes almost everything about how they are made, copied, and regulated. When companies attempt to develop biosimilar versions of these complex therapies, they quickly encounter a fundamental reality: you cannot make a perfect replica of a molecule produced by a biological system. What you can do is demonstrate, through rigorous side-by-side testing, that your version behaves in essentially the same way. Regulators have built a framework around this reality — one that demands thorough quality comparisons but reduces the clinical evidence bar once similarity has been convincingly shown. Still, the biological complexity of these molecules and the relatively short track record of biosimilars in clinical practice mean regulators remain cautious about declaring them fully interchangeable with the original products, a position that carries real implications for how doctors prescribe and how pharmacists dispense them. [1] When patents on blockbuster biologics eventually expire, the door opens for biosimilar competitors — and the effects on healthcare markets can be substantial. Competition drives prices down, and the savings have accumulated to billions of dollars globally. More importantly for patients, therapies that were once unaffordable have become accessible to a far wider population. Nowhere is this more vividly illustrated than in Eastern Europe. In countries like Bulgaria, the Czech Republic, and Romania, access to epoetin treatments had long been out of reach for most patients who needed them. The arrival of biosimilar alternatives cut prices nearly in half and drove utilization up by more than 250%   a remarkable demonstration of what happens when economic barriers to biological therapies are removed. [2] This review sets out to unpack all of this in depth. It examines what makes biologics so fundamentally different from ordinary generic drugs, and why those differences matter so much in practice. It walks through the regulatory pathways that govern biosimilar approvals around the world, the manufacturing challenges that make biological production so demanding, and the clinical questions around safety, effectiveness, immune responses, and substitutability that remain actively debated. The economic landscape, including how biosimilar adoption is reshaping global healthcare spending, receives close attention as well. Throughout, the aim is to give readers a clear-eyed view of where the field stands today, what obstacles remain, and what a more accessible and scientifically mature biosimilar landscape might look like in the years ahead. [3]

Table 1. The Differences Between Small-Molecule Medicines & Biological Medicines

Overview of biologics

Definition and characteristics

Biopharmaceuticals, also known as biological medicines, are a specialized class of therapies derived from living systems or produced using recombinant DNA and gene expression technologies. Unlike conventional small-molecule drugs, they are composed of large and complex macromolecules such as proteins, glycoproteins, and nucleic acids, which contribute to their high specificity and therapeutic effectiveness. Their production is highly complex and influenced by multiple factors, including the choice of expression system, cell culture conditions, purification processes, and storage methods. Additionally, post-translational modifications like glycosylation and phosphorylation introduce natural variability that can affect their biological activity. Biopharmaceuticals are also more sensitive to environmental conditions, making them prone to instability such as degradation or aggregation. In contrast, small-molecule drugs are simpler, chemically synthesized, and more stable, with predictable properties and easier manufacturing. Due to these differences, biopharmaceuticals require more stringent development, characterization, and regulatory approaches. [4, 5]

Types of biologics:-

Unlike conventional drugs which are chemically synthesized and yield well-defined, predictable molecules biologics are produced from or within living biological systems, making them far more structurally complex. They broadly fall into three functional categories: monoclonal antibodies, receptor modulators, and enzyme-replacement or enzyme-modulating agents. Manufacturing them is a technically demanding process that typically involves gene isolation, recombinant DNA engineering, and advanced protein purification, carried out using platforms ranging from mammalian cell lines to microbial and plant-based systems. Because of their size and structural sensitivity, biologics also require carefully designed formulations containing stabilizers and preservatives components that can meaningfully influence the drug's pharmacokinetics, pharmacodynamics, and overall biological activity. [6, 7] Biologics span several major therapeutic categories, each with a distinct mechanism of action:

Monoclonal antibodies are laboratory-engineered proteins designed to bind with high precision to specific targets — such as cancer cell antigens or infectious pathogens triggering their destruction or modulating immune responses. Well-known examples include rituximab and adalimumab.

Recombinant proteins are produced via recombinant DNA technology to replace proteins the body is missing or unable to produce correctly. Recombinant insulin and various growth factors are among the most widely used examples.

Vaccines prepare the immune system to recognize and fight specific pathogens, conferring lasting protection through immunological memory.

Cell-based therapies involve introducing living cells particularly stem cells into patients to repair or regenerate damaged tissues, representing one of the most rapidly advancing areas of regenerative medicine.

Gene therapies work at the genetic level, correcting, replacing, or modifying defective DNA or RNA sequences to address the root cause of disease rather than just its symptoms. Together, these agents primarily work by targeting components of the immune system or restoring proteins that are absent or dysfunctional in patients.

Figure 1. Types of Biologics

Because biopharmaceuticals come from living biological systems, the risk of triggering an immune response is an ever-present concern in clinical practice. These reactions can cause two distinct problems: they may provoke allergic or hypersensitivity reactions in some patients, and they can interfere with how the drug works sometimes to a serious degree. When the immune system mounts a response against the biologic itself, or against components of its formulation, the drug's effectiveness can gradually erode, leading to reduced efficacy or, in some cases, complete treatment failure. A particularly worrying though relatively rare scenario arises when the antibodies generated against the biologic cross-react with the body's own naturally occurring proteins. This phenomenon, sometimes described as molecular mimicry, can produce serious clinical consequences. A well-documented example is pure red cell aplasia, a severe blood disorder seen in some patients receiving epoetin therapy. In these cases, neutralizing antibodies raised against the recombinant protein also attack the patient's endogenous erythropoietin, effectively shutting down red blood cell production. Though uncommon, this illustrates just how consequential immunogenic responses to biologics can be when they extend beyond the drug itself. [8]

Manufacturing of Biologics

Figure 2. The process of producing biologics today

Cell line Development

Building a stable, high-yielding cell line is one of the most technically demanding steps in biopharmaceutical manufacturing — and one of the most important. The process begins with genetic engineering: the gene responsible for producing the target therapeutic protein is inserted into mammalian host cells in a way that ensures it is expressed reliably and consistently over time. From there, large numbers of candidate cell clones are screened and compared to identify those that produce the protein at the highest levels with the greatest stability. The most promising clones are then thoroughly characterized to confirm their genetic integrity, expression consistency, and biological function. Finally, the validated cell lines are preserved through a structured banking system comprising both master and working cell banks  ensuring they remain available for future production runs and that manufacturing remains reproducible batch after batch.

Table 2. Key stages in monoclonal antibody cell line development include:-

Cell line development is the backbone of biologics manufacturing, directly determining the efficiency and scalability of monoclonal antibody and recombinant protein production. Each stage host cell selection, genetic modification, clone screening, and cell banking is critical to achieving stable, high-yield protein expression. Chinese Hamster Ovary (CHO) cells have become the undisputed industry standard, thanks to continuous engineering advances that have delivered higher production titres, better genomic stability, and smoother regulatory pathways. Their versatility makes them the go-to platform for producing complex biologics, particularly monoclonal antibodies. Next-generation CHO-K1 systems are pushing boundaries further still. Technologies like transposase-mediated gene integration enable more precise, stable transgene insertion translating into more consistent expression, greater scalability, and stronger overall manufacturing performance. These advances are steadily reshaping expectations across the biologics industry. [9]

Upstream / downstream processing

Upstream processing is the first major phase of biologics manufacturing, covering everything that happens before purification begins cell line banking, culture media preparation, and the controlled cultivation of cells in bioreactors, culminating in harvest. The goal is straightforward: establish a stable, reproducible bioprocess that generates the target protein in sufficient quantities while meeting the quality standards required for regulatory approval and clinical use. The process typically starts from a single frozen vial of the engineered production cell line. This seed stock is gradually expanded through successive culture stages, with critical parameters temperature, pH, dissolved oxygen, and nutrient levels carefully monitored and adjusted throughout. Once the cells reach the required density and viability, they are transferred into progressively larger bioreactors for full-scale production. Scientists continually refine feeding strategies to maximize protein yield while keeping cells healthy enough to sustain productivity across the entire production run. Striking the right balance matters: while rapid cell growth is desirable early on, overly dense cultures can exhaust nutrients and accumulate toxic waste products, undermining productivity. Downstream processing picks up where upstream leaves off its purpose is to isolate and purify the target biologic from the complex mixture of cells, proteins, and impurities produced during cultivation. Using a sequence of techniques including depth filtration, tangential flow filtration, and multi-step chromatography, this phase systematically removes host cell proteins, residual nucleic acids, and other contaminants. The end result is a highly purified, appropriately concentrated product ready for therapeutic use, further formulation, or analytical testing much like how a chemist purifies a reaction mixture to obtain a compound of defined quality and composition. [10, 11]

Figure 3. Upstream and downstream processing

Quality Attributes and Variability

Biosimilar development hinges on one core requirement: proving the candidate is highly similar to the reference product in both structure and function. Even minor manufacturing deviations can alter the product's properties, making rigorous process optimization non-negotiable from the outset. Development begins with transfecting a host cell line often different from the originators with a DNA vector encoding the target molecule. However, replicating the amino acid sequence alone is insufficient. Higher-order structures and post-translational modifications (PTMs) that govern biological activity are heavily shaped by the cellular environment and process conditions, meaning sequence accuracy does not guarantee functional equivalence. Quality-by-Design (QbD) has become the standard framework for navigating this complexity, requiring developers to understand how variations in process parameters, raw materials, and equipment influence critical quality attributes and to use that knowledge to engineer similarity systematically. Full structural characterization spanning primary through higher-order architecture, PTM profiles, and biological activity is mandatory, with the reference product serving as the constant benchmark. Monoclonal antibody biosimilars with antibody-dependent cellular cytotoxicity (ADCC) activity illustrate this challenge well: the glycan structures on the antibody's Fc region critically influence function and must be precisely controlled alongside multiple other interdependent quality attributes. Culture conditions, purification processes, and formulation strategies are all carefully optimized to ensure the biosimilar consistently matches the reference product across all clinically relevant attributes and remains stable throughout its intended shelf life. [12]

Figure 4. Iterative steps in the process development and analytical similarity assessment for a proposed biosimilar product. DP drug product, DS drug substance.

Biosimilar: - Concept and Development

A biosimilar is a biological medicine designed to be highly similar to an already approved biologic, known as the reference product. Like the original, it is produced using complex living systems and shares the same type of large, structurally intricate molecules that characterize biopharmaceuticals. A key feature of biologics and biosimilars is that the manufacturing process directly influences the final product. Since each biologic is made through a unique process, creating an exact copy is not possible. As a result, biosimilars are not identical but are developed to be very close in structure and function, with only minor acceptable differences arising from variations in production methods. Regulatory pathways ensure that biosimilars match their reference products in terms of quality, safety, and effectiveness. However, small differences may occasionally lead to slight variations in side effects, which is why continuous monitoring through pharmacovigilance is essential even after approval. [13]

Define vs. Principles of biosimilarity

The combined effects of global population ageing and societal modernization have precipitated a marked epidemiological shift, with non-communicable diseases encompassing malignancies, diabetes mellitus, chronic kidney disease, and chronic inflammatory disorders now representing the leading causes of mortality worldwide. This transition carries significant implications for long-term patient management, particularly given the progressive and interconnected nature of these conditions. Patients with advanced type 2 diabetes frequently require insulin analogues spanning a broad range of formulation profiles long-acting, short-acting, ultra-short-acting, and ultra-long-acting — tailored to individual glycaemic control needs. Disease progression may further necessitate erythropoiesis-stimulating agents such as erythropoietin to address renal failure-associated anaemia. Given the well-established links between diabetes and oncological disease, affected patients may additionally require biologics or biosimilars for cancer management or drug-induced neutropenia. Notably, the relationship is bidirectional — anticancer interventions such as hormone-based therapies or surgical pancreatectomy may themselves precipitate diabetes, resulting in therapeutically complex clinical scenarios requiring coordinated multidisciplinary management. [14, 42]

Higher Similar, not identical

Unlike small-molecule generics — which are chemically identical to their branded counterparts biosimilars are comparable but not structurally identical to their reference biologics. This distinction stems directly from the molecular complexity of biological products and the process-dependent nature of their manufacture. Both the EMA and FDA have established rigorous approval frameworks to address this. The EMA requires biosimilars to demonstrate high comparability to the reference product across molecular structure, biological activity, safety, efficacy, and immunogenicity. The FDA, under the Biologics Price Competition and Innovation Act (BPCIA), requires that biosimilars show no clinically meaningful differences in safety, purity, and potency. In both frameworks, minor physicochemical differences are acceptable but only when robust evidence confirms they have no impact on clinical performance. [15]

Stepwise Development Approach

The scientific foundation of biosimilar development rests on the principle of comparability originally developed to manage manufacturing changes in approved biologics, and later adapted as the conceptual backbone of biosimilarity assessment. In practice, developers follow a structured, stepwise approach built around the totality-of-evidence paradigm. The process begins with exhaustive analytical characterization, where the biosimilar's structural, functional, and quality attributes are rigorously compared against the reference product using state-of-the-art methods. From there, a targeted programme of non-clinical and clinical studies is conducted to confirm that any differences identified at the analytical level do not translate into clinically meaningful distinctions in safety, efficacy, or immunogenicity. [16]

Figure 5. Stepwise development pathway for biosimilars

Analytical Characterization

Advances in analytical science now allow detailed characterization of not only the active biologic but also its excipients and impurities. When combined with existing knowledge of the reference product, this makes thorough characterization the foundation of biosimilar development. A central step is the physicochemical comparison between the biosimilar and the reference product, ensuring that all attributes remain within statistically defined limits based on variability observed across multiple reference batches. These studies also provide insight into the manufacturing process, expression system, and product stability. [17,18] Comprehensive analytical evaluation supports comparison of structural and functional features such as biological activity, target binding, immunochemical properties, impurity profiles, and overall product stability. Regulatory bodies like the FDA stress that, along with identifying critical quality attributes, the sensitivity and limitations of analytical methods and statistical tools must be carefully considered. To strengthen reliability, the FDA recommends using orthogonal methods—multiple techniques based on different principles and including samples from U.S. and European reference batches, pharmacopoeia standards, and test batches. [18, 19] Filgrastim, a non-pegylated recombinant G-CSF marketed as Neupogen by Amgen, is widely used to manage chemotherapy-induced neutropenia by reducing infection risk and supporting neutrophil recovery. Its biosimilar, Zarxio by Sandoz, was approved via the 351(k) pathway based on comparative studies involving several batches from both the biosimilar and reference products across different regions. [20,21]

Table3. The most important CQAs selected for Zarxio

Non-Clinical Studies

Preclinical disease models provide valuable dose-response insights when both the biosimilar and reference product show cross-reactivity in a relevant animal species. Evaluating doses within the steep region of the dose-response curve maximizes sensitivity for detecting meaningful differences in biological activity. This is especially relevant in oncology biosimilar development, where the lack of well-defined PD biomarkers makes equivalence assessment difficult. Humanized tumor-bearing models allow direct head-to-head dose comparisons and can support extrapolation of biosimilarity across untested indications. Preclinical programs should cover comparative PK/PD, toxicology, and immunogenicity profiling but only where a pharmacologically relevant species is available. As analytical and in vitro evidence accumulates, the need for animal testing diminishes, and minimizing animal use in line with the 3Rs framework should be actively pursued. A targeted repeat-dose toxicology study potentially restricted to a single high dose and one sex  is often sufficient to confirm comparable toxicity profiles. Cell-based bioactivity assays are an increasingly preferred alternative to animal studies, offering strong mechanistic sensitivity and potentially reducing the broader evidence burden when adequately validated. Animal immunogenicity data, where included, should be interpreted cautiously useful for detecting qualitative differences in immunogenic potential, but not a reliable predictor of human outcomes. [21, 22]

Clinical Studies

The primary goal of a biosimilar's clinical development programme is to conclusively demonstrate no clinically meaningful differences in safety, efficacy, and immunogenicity compared to the reference product. The scope of required clinical evidence is not fixed it is calibrated proportionally to the similarity already established through preceding analytical and preclinical work, reflecting a risk-based, stepwise approach. For monoclonal antibodies and other complex biologics such as fusion proteins, comparative clinical trials are likely to remain mandatory. The frequent absence of well-validated PD biomarkers means clinical efficacy studies cannot easily be replaced by surrogate measures, and are needed both to confirm therapeutic equivalence and to adequately characterize safety risks. [23, 24] Clinical development typically begins with a rigorously designed pharmacokinetic (PK) similarity study, with comparative human PK and/or PD assessments forming the essential foundation of the biosimilarity evidence package.[25, 26]

Extrapolation of Indications

Achieving these goals requires a coordinated multidisciplinary effort, supported by strong institutional frameworks that promote treatment adherence, continuous monitoring, and post-marketing surveillance. As more biologics lose patent protection, biosimilar availability is set to expand extending access to broader patient populations, including those in low- and middle-income countries where non-communicable diseases are rising rapidly. To fully realize this potential, nations must build robust regulatory infrastructures covering the entire biologic lifecycle from manufacturing standards and supply chain integrity to substitution policies, expanded indications, and post-approval safety monitoring. [27] At the clinical level, a significant knowledge gap persists among practicing physicians regarding the breadth and versatility of biologic therapies. Clinicians must proactively engage with evolving treatment paradigms, understand cross-indication biologic use, carefully weigh risks against benefits, and rigorously evaluate patient outcomes. Beyond direct patient care, physicians also have a responsibility to advocate engaging health authorities, insurers, and manufacturers to champion equitable access to safe, effective, and high-quality therapies, with biologics playing a central role in that effort.[28]

Global Regulatory Guidelines

World Health Organization (WHO)

As biosimilars referred to by WHO as Similar Biotherapeutic Products (SBPs) began entering development pipelines and gaining approval worldwide, WHO recognized the need for a standardized regulatory framework. This led to the adoption of the "Guidelines on Evaluation of Similar Biotherapeutic Products" at the 60th WHO Expert Committee on Biological Standardization meeting in 2009. The guidelines establish universal principles for licensing SBPs that are comparable to already-approved reference products, focusing primarily on well-characterized recombinant DNA-derived therapeutic proteins with established quality, safety, and efficacy profiles. [29]

United States (FDA)

In the US, the approval pathway for biosimilars depends on the legislation under which the original biologic was authorized either the Food, Drug, and Cosmetic Act (FD&C Act) or the Public Health Service Act (PHS Act). [30] The landmark Biologics Price Competition and Innovation (BPCI) Act, passed in March 2010, amended the PHS Act to create an abbreviated approval pathway for biologics that are highly similar to or interchangeable with an FDA-approved reference product, codified under Section 351(k). Early-generation biologics originally approved under the FD&C Act such as insulin and somatropin may instead seek biosimilar approval via a Section 505(b)(2) New Drug Application. [31, 32]

Interchangeability and Substitution

Interchangeability refers to replacing one biologic with another expected to deliver equivalent clinical outcomes. The EU takes a straightforward position EMA approval inherently confers interchangeability, allowing biosimilars to replace their originator or another biosimilar with the same reference product. Switching (physician-directed) and substitution (pharmacy-level, without prescriber involvement) are both recognized practices, regulated at the individual member state level. [33,34] The US takes a stricter approach, requiring multiple switch studies before granting a formal interchangeability designation that permits pharmacy-level substitution though prescribers can always override this by specifying the product by name. [35, 36]

Clinical implications

A biosimilar's clinical programme is fundamentally comparative — designed to confirm equivalence rather than independently establish safety and efficacy from scratch. Its scope is directly shaped by the strength of preclinical comparability data; robust analytical and functional evidence can substantially reduce the clinical burden. The FDA acknowledges that formal efficacy trials may be unnecessary when preclinical data have adequately resolved outstanding uncertainties. However, human safety and immunogenicity studies cannot be bypassed these endpoints are inherently unpredictable from preclinical data alone and require adequately powered studies with sufficient follow-up and sensitive assays. [37]

Country-specific differences

The multiple-switch PK studies currently required for US interchangeability designation appear scientifically redundant in light of existing evidence, and a reassessment of this separate designation is warranted. More broadly, misconceptions about biosimilar safety, efficacy, and substitutability remain a significant barrier to clinical uptake — regardless of interchangeability status. [37]

Quality, Safety, and Immunogenicity

The evaluation of biosimilar efficacy and safety has been conducted through rigorously designed randomized, double-blind clinical trials, with therapeutic indications selected on the basis of their capacity to yield a reliable and quantifiable estimate of treatment effect informed by prior clinical experience with the originator product. To ensure the most meaningful and discriminating comparison, the primary efficacy endpoints chosen for these trials were those considered most sensitive to detecting any potential differences between the biosimilar and its reference product. Across all biosimilar monoclonal antibodies (mAbs) and etanercept-based products evaluated, the predefined equivalence criteria for efficacy were successfully met, providing robust evidence in support of their comparability to the respective originators. [38] Comparative immunogenicity studies constitute a mandatory component of the biosimilar development program. In accordance with regulatory requirements, such studies have been systematically conducted and subsequently documented within the European Public Assessment Reports (EPARs) for all relevant biosimilar products, ensuring transparency and scientific rigor throughout the approval process. [39,40]

Analytical Comparability

Comparability assessment is widely accepted as a reliable and sensitive scientific approach for evaluating changes in biologic products, whether due to manufacturing modifications or the development of biosimilars by different manufacturers. Its evolution has been supported by clearer regulatory guidelines, risk-based evaluation strategies, advances in analytical technologies, and improved understanding of post-translational modifications. [41] The main goal of comparability assessment is to confirm that two biologic versions show no meaningful differences in safety or efficacy. It is essential when manufacturing processes change or when biosimilars are developed, ensuring consistent clinical performance. [42, 43]

Immunogenicity Causes

Immunogenicity testing is a crucial part of biosimilar development, as increased anti-drug antibody (ADA) responses compared to the reference product may indicate underlying quality differences. The immune response to therapeutic proteins is influenced by multiple factors, including structural variations, impurities, formulation, administration route, and patient-related characteristics. However, in biosimilars, patient population and route of administration remain the same as the reference product, narrowing the focus to product-related factors such as molecular structure, impurity levels, and formulation. Key contributors to immunogenicity include differences in glycosylation patterns, oxidative changes, and protein aggregation, all of which can alter how the immune system recognizes the drug. [44]

Clinical Consequences

Immunogenicity can lead to varied clinical outcomes, ranging from mild to severe. For example, infliximab has been associated with infusion reactions and delayed adverse effects due to ADA formation. A more serious case involved recombinant erythropoietin, which caused pure red cell aplasia, a life-threatening condition. In contrast, some biologics like rituximab show minimal clinical impact despite detectable ADA levels. These differences highlight the product-specific nature of immunogenicity. Therefore, strict regulatory guidelines require thorough immunogenicity evaluation to ensure the safety and efficacy of biosimilars. [45]

Figure 6. Immunogenicity

Mitigation Strategies

Literature identifies several practical strategies to support successful biosimilar switching, focusing on effective communication, education, and organized clinical practices. These include clear and positive communication, empathetic interaction, shared decision-making, and patient reassurance techniques. [46] A key challenge in biosimilar adoption is the nocebo effect, where negative expectations about biosimilars can lead to perceived reduced efficacy, increased reporting of side effects, or treatment discontinuation—despite no actual difference from the original biologic. These responses are driven mainly by lack of awareness and confidence. [47] To address this, a coordinated approach combining communication, education, and patient involvement is essential. Such strategies help minimize the nocebo effect, ensure smoother transitions, and promote wider acceptance of biosimilars in clinical practice. [48]

Pharmacovigilance
Biologics and biosimilars are complex products derived from living systems, making them more prone to risks such as immunogenicity and batch variability. These risks may not be fully detected during clinical trials due to limited patient exposure, highlighting the need for strong pharmacovigilance systems. Post-marketing surveillance plays a vital role in monitoring long-term safety and identifying rare or unexpected adverse events in real-world settings. [49 ,50] Pharmacovigilance involves not only reporting adverse drug reactions (ADRs) but also tracking drug interactions, medication errors, and therapeutic failures. Regulatory bodies like the EMA, FDA, and India’s PvPI have established guidelines to ensure effective safety monitoring. Marketing authorization holders must maintain robust systems for ADR collection, ensure timely reporting, and collaborate with partners through safety agreements. Accurate documentation, including brand name and batch number, is essential to detect product-specific safety issues. [51,52]

Post-Marketing Surveillance and Traceability

Effective safety monitoring is often challenged by incomplete recording of product details, especially batch numbers, which limits traceability. Studies show that while brand names are often reported, batch numbers are frequently missing. Improving data recording systems in clinical settings is therefore critical to enhance traceability, ensure patient safety, and strengthen pharmacovigilance practices. [53, 54]

Figure 7. Brand name and batch number reporting over time

Clinical Applications of Biosimilars

Biologics are advanced therapeutic proteins produced using living cells, designed to either mimic natural biological functions or block disease-causing pathways. Their high specificity and complex structure enable targeted treatment across multiple medical fields, including cancer, autoimmune disorders, and hormonal diseases. Biosimilars extend these benefits by providing more affordable alternatives, improving patient access without compromising efficacy or safety. [55,56]

Oncology
In cancer treatment, biologics and biosimilars play a key role in targeted therapy, improving survival and disease management. With the global cancer burden rising, these therapies are increasingly important in addressing major cancers such as breast, lung, and colorectal cancer, offering more precise and effective treatment options. [57,58]

Gastroenterology
In inflammatory bowel diseases like Crohn’s disease and ulcerative colitis, biosimilars of anti-TNF agents (e.g., infliximab) have significantly improved patient outcomes. They have demonstrated comparable efficacy and safety, while also reducing treatment costs and expanding access to long-term therapy. [59,60]

Rheumatology
In conditions like rheumatoid arthritis, biosimilars of biologic DMARDs help manage inflammation and prevent disease progression. By reducing costs, they make advanced therapies more accessible, especially for patients who do not respond adequately to conventional treatments. Overall, biosimilars are transforming clinical practice by maintaining therapeutic effectiveness while enhancing affordability and accessibility across major disease areas. [61, 62]

Economics and Healthcare Impact

Cost Savings and Market Competition

Biologic therapies, despite their high development costs, have become essential in treating many serious and chronic diseases due to their targeted action and strong clinical outcomes. Their global demand is reflected in the success of several blockbuster biologics generating billions in revenue. However, as patents for these products expire, biosimilars are entering the market, creating opportunities for more affordable treatment options. Regulatory agencies are supporting this shift by enabling faster approval pathways, encouraging competition, and ultimately reducing healthcare costs while improving patient access. [63,64]

Market Competition

India has established itself as a key player in the global biosimilar market, with over 20 companies actively involved in development and more than 70 approved biosimilar products. The country’s biotechnology sector is rapidly expanding, supported by strong growth and increasing global recognition. With its large-scale manufacturing capacity and cost-efficient production, India is well-positioned to drive future growth in the biosimilar industry. Overall, biosimilars not only reduce treatment costs but also strengthen market competition, making advanced therapies more accessible worldwide. [65,66]

Challenges and Limitations

The development and use of biologics and biosimilars face several challenges that limit their full potential, particularly in areas such as manufacturing, acceptance, legal frameworks, and global access.

Manufacturing Complexity
Biologic production is highly complex because it relies on living cells, unlike simpler chemical drugs. The process involves advanced bioreactor systems, careful purification, and strict quality control to maintain product consistency. It is time-consuming, often taking many months, and requires significant financial investment, making it one of the most demanding areas in pharmaceutical manufacturing. [67,68]

Physician and Patient Acceptance
Adoption of biosimilars is also influenced by patient and physician preferences. Factors such as dosing frequency, convenience, and place of administration play important roles. While many prefer less frequent dosing and home-based treatment for convenience, some patients still favor clinical settings for safety reassurance. Acceptance tends to improve with prior experience and better awareness.[69,70]

Legal and Patent Challenges
Biologics are protected by complex patent systems that cover not only the drug itself but also its manufacturing process and formulation. Even after primary patents expire, multiple secondary patents can delay biosimilar entry, requiring companies to navigate complicated legal pathways. [71, 72]

Global Inequality in Access
High costs of biologics limit access, especially in low- and middle-income regions. Biosimilars offer a practical solution to improve affordability, but wider adoption depends on increased awareness, supportive policies, and collaboration among healthcare stakeholders to ensure equitable access to treatment. [73]

Table 4. Biologics, Biosimilar, Biobetters differences